Cambridge Investment Research Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $143M | Buy |
566,381
+14,061
| +3% | +$3.03M | 0.32% | 50 |
|
|
2026
Q1 | $120M | Buy |
552,320
+7,103
| +1% | +$1.58M | 0.31% | 47 |
|
|
2025
Q4 | $125M | Buy |
545,217
+9,761
| +2% | +$2.22M | 0.33% | 45 |
|
|
2025
Q3 | $124M | Buy |
535,456
+13,663
| +3% | +$2.78M | 0.34% | 44 |
|
|
2025
Q2 | $96.9M | Buy |
521,793
+10,733
| +2% | +$1.99M | 0.29% | 52 |
|
|
2025
Q1 | $107M | Buy |
511,060
+21,249
| +4% | +$4.13M | 0.36% | 45 |
|
|
2024
Q4 | $87M | Sell |
489,811
-5,260
| -1% | -$967K | 0.29% | 57 |
|
|
2024
Q3 | $97.8M | Buy |
495,071
+17,804
| +4% | +$3.32M | 0.33% | 47 |
|
|
2024
Q2 | $81.9M | Sell |
477,267
-1,943
| -0.4% | -$322K | 0.3% | 51 |
|
|
2024
Q1 | $87.3M | Sell |
479,210
-8,532
| -2% | -$1.47M | 0.34% | 47 |
|
|
2023
Q4 | $75.6M | Sell |
487,742
-44,986
| -8% | -$6.56M | 0.32% | 52 |
|
|
2023
Q3 | $79.4M | Buy |
532,728
+23,693
| +5% | +$3.48M | 0.37% | 48 |
|
|
2023
Q2 | $68.6M | Sell |
509,035
-10,060
| -2% | -$1.48M | 0.31% | 50 |
|
|
2023
Q1 | $82.7M | Sell |
519,095
-26,828
| -5% | -$4.1M | 0.41% | 40 |
|
|
2022
Q4 | $88.2M | Buy |
545,923
+10,284
| +2% | +$1.58M | 0.46% | 36 |
|
|
2022
Q3 | $71.9M | Buy |
535,639
+22,820
| +4% | +$3.27M | 0.41% | 42 |
|
|
2022
Q2 | $78.5M | Sell |
512,819
-24,732
| -5% | -$3.78M | 0.42% | 39 |
|
|
2022
Q1 | $87.1M | Buy |
537,551
+13,392
| +3% | +$1.95M | 0.4% | 37 |
|
|
2021
Q4 | $71M | Sell |
524,159
-9,067
| -2% | -$1.07M | 0.32% | 55 |
|
|
2021
Q3 | $57.5M | Buy |
533,226
+19,349
| +4% | +$2.21M | 0.28% | 60 |
|
|
2021
Q2 | $57.9M | Buy |
513,877
+27,127
| +6% | +$3.06M | 0.28% | 67 |
|
|
2021
Q1 | $52.7M | Buy |
486,750
+54,226
| +13% | +$5.8M | 0.29% | 64 |
|
|
2020
Q4 | $46.3M | Sell |
432,524
-12,175
| -3% | -$1.17M | 0.27% | 67 |
|
|
2020
Q3 | $39M | Buy |
444,699
+30,912
| +7% | +$2.91M | 0.26% | 71 |
|
|
2020
Q2 | $40.6M | Buy |
413,787
+40,600
| +11% | +$3.57M | 0.31% | 61 |
|
|
2020
Q1 | $28.4M | Buy |
373,187
+24,827
| +7% | +$2.11M | 0.27% | 73 |
|
|
2019
Q4 | $30.8M | Buy |
348,360
+32,250
| +10% | +$2.68M | 0.24% | 84 |
|
|
2019
Q3 | $23.9M | Buy |
316,110
+54,557
| +21% | +$3.74M | 0.21% | 99 |
|
|
2019
Q2 | $19M | Buy |
261,553
+28,699
| +12% | +$2.26M | 0.17% | 123 |
|
|
2019
Q1 | $18.8M | Buy |
232,854
+8,422
| +4% | +$689K | 0.18% | 118 |
|
|
2018
Q4 | $20.7M | Buy |
224,432
+8,840
| +4% | +$777K | 0.23% | 94 |
|
|
2018
Q3 | $20.4M | Buy |
215,592
+10,163
| +5% | +$964K | 0.19% | 115 |
|
|
2018
Q2 | $19M | Buy |
205,429
+860
| +0.4% | +$84K | 0.2% | 112 |
|
|
2018
Q1 | $19.4M | Buy |
204,569
+2,464
| +1% | +$271K | 0.22% | 100 |
|
|
2017
Q4 | $19.5M | Buy |
202,105
+19,119
| +10% | +$1.8M | 0.23% | 93 |
|
|
2017
Q3 | $16.3M | Sell |
182,986
-13,252
| -7% | -$1.01M | 0.22% | 92 |
|
|
2017
Q2 | $14.2M | Buy |
196,238
+18,778
| +11% | +$1.26M | 0.21% | 94 |
|
|
2017
Q1 | $11.6M | Buy |
177,460
+24,738
| +16% | +$1.56M | 0.2% | 101 |
|
|
2016
Q4 | $9.56M | Buy |
152,722
+23,117
| +18% | +$1.41M | 0.18% | 114 |
|
|
2016
Q3 | $8.17M | Buy |
129,605
+7,945
| +7% | +$514K | 0.15% | 121 |
|
|
2016
Q2 | $7.53M | Buy |
121,660
+4,228
| +4% | +$258K | 0.16% | 124 |
|
|
2016
Q1 | $6.71M | Buy |
117,432
+4,686
| +4% | +$261K | 0.15% | 123 |
|
|
2015
Q4 | $6.68M | Buy |
112,746
+7,763
| +7% | +$447K | 0.16% | 123 |
|
|
2015
Q3 | $5.71M | Sell |
104,983
-2,753
| -3% | -$179K | 0.16% | 130 |
|
|
2015
Q2 | $7.24M | Buy |
107,736
+8,710
| +9% | +$569K | 0.2% | 106 |
|
|
2015
Q1 | $5.8M | Buy |
99,026
+6,124
| +7% | +$370K | 0.17% | 127 |
|
|
2014
Q4 | $6.08M | Sell |
92,902
-35
| -0% | -$2.21K | 0.19% | 112 |
|
|
2014
Q3 | $5.37M | Buy |
92,937
+4,358
| +5% | +$242K | 0.16% | 135 |
|
|
2014
Q2 | $5M | Buy |
88,579
+5,050
| +6% | +$265K | 0.17% | 118 |
|
|
2014
Q1 | $4.29M | Buy |
83,529
+5,658
| +7% | +$286K | 0.16% | 125 |
|
|
2013
Q4 | $4.11M | Buy |
77,871
+2,176
| +3% | +$107K | 0.17% | 124 |
|
|
2013
Q3 | $3.39M | Buy |
75,695
+1,437
| +2% | +$63.7K | 0.15% | 143 |
|
|
2013
Q2 | $3.07M | Buy |
+74,258
| New | +$3.25M | 0.16% | 134 |
|
Other funds holding ABBV
ECSS
ATO
Cambridge Investment Research Advisors's ABBV Position: Q2 2026 in Review
Cambridge Investment Research Advisors increased its AbbVie (ABBV) stake by 2.5% in Q2 2026, buying an estimated $3.03M and bringing the position to 566,381 shares worth $143M. The position accounts for 0.32% of the portfolio, ranked #50.
Cambridge Investment Research Advisors first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 2,113 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Cambridge Investment Research Advisors held 566,381 shares of AbbVie worth $143M as of Q2 2026.
- Cambridge Investment Research Advisors bought 14,061 AbbVie shares in Q2 2026, an estimated $3.03M.
- AbbVie made up 0.32% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #50 holding.
- Cambridge Investment Research Advisors first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
- 2,113 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.